[Info-congress. COPERNICUS and Val-HEFT studies].
Kulbertus
H
H
Université de Liège, Chef du Service de Cardiologie.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D003327:Coronary Disease / Q000188:drug therapy* / Q000401:mortality; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D011412:Propanolamines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D013777:Tetrazoles / Q000627:therapeutic use*; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000068756:Valsartan
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002227:Carbazoles; D011412:Propanolamines; D013777:Tetrazoles; D000077261:Carvedilol; D000068756:Valsartan; D014633:Valine
Info-congrès. Les études Copernicus et Val-HEFT.